ArticleViruses2026
Seroprevalence of Hepatitis A Virus (HAV) and Hepatitis E Virus (HEV) Among Blood Donor Candidates in Salvador, Bahia, Brazil.
Article in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis A (HAV) and E (HEV) are clinically indistinguishable diseases. This study aimed to determine the seroprevalence of both viruses among 469 blood donor candidates at HEMOBA, Salvador, Brazil. The seroprevalence of anti-HAV IgG was determined by chemiluminescence (Abbott Diagnostics, Chicago, IL, USA) and that of anti-HEV (IgG/IgM) was determined by ELISA (Wantai-Biopharm, Beijing, China). The ineligibility rate was 16.8% (79/469), mostly temporary. There were no statistically significant demographic differences between ineligible and eligible donor candidates. The participants were predominantly male (52.7%), with the skin color Brown/Black (83.2%), and had completed secondary education or started/completed higher education (89.6%). The seroprevalence of anti-HAV IgG was 53.5% (193/361; 95%CI: 48.2-58.7%) among unvaccinated participants; the seroprevalence of anti-HEV IgG was 7.0% (33/469; 95%CI: 4.9-9.7%), and no case of anti-HEV IgM was found. In univariate analysis, HAV was associated with work with livestock and eating fresh fish; HEV was related to low incomes and eating game meat. However, only aging and being born in the interior of the state retained statistical significance in the final model. In conclusion, despite the availability of the HAV vaccine, this study revealed a higher burden of HAV when compared to HEV. Future studies must prioritize risk factor investigations of both viruses in non-metropolitan and rural areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.